Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y12 receptor. The drug is produced by AstraZeneca. WebJun 29, 2024 · Although rates of major bleeding were not statistically different between ticagrelor and clopidogrel in the Study of Platelet Inhibition and Patient Outcomes (PLATO) trial, the rates of other bleeding types, such as non‐CABG‐related major bleeding, were significantly higher in ticagrelor, and observational studies have consistently …
Ticagrelor - HealthHub
WebJun 18, 2012 · Ticagrelor, like other antiplatelet agents, can cause significant, sometimes fatal, bleeding. Do not use ticagrelor in patients with active pathological bleeding or a … WebTicagrelor is an anti-platelet medication. It is usually used in people who have symptoms of chest pain (angina) or who have had a heart attack (myocardial infarction) to reduce the … corolla n c weather for weekend
Ticagrelor Oral: Uses, Side Effects, Interactions, Pictures ... - WebMD
WebTicagrelor C23H28F2N6O4S CID 9871419 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities ... WebSep 27, 2024 · Ticagrelor is used in the treatment of Prevention of heart attack and stroke. View Ticagrelor’s uses, side-effects, drug interactions, expert advice and user FAQs only … WebNICE TA236. Ticagrelor for the treatment of acute coronary syndromes (October 2011) Recommended. NICE TA420. Ticagrelor for preventing atherothrombotic events after myocardial infarction (December 2016) Recommended. fantech mp44